Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 03 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Dishman Carbogen Amcis Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, signalling increased bearishness despite a modest intraday price gain. Recent technical indicators reveal a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, underscoring the challenges facing the stock amid broader market pressures.

Dishman Carbogen Amcis Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Dishman Carbogen Amcis Ltd experienced a significant decline today, touching an intraday low of Rs 170.3 as the stock faced intense selling pressure. The pharmaceutical and biotechnology company underperformed its sector and broader market indices, reflecting a continuation of recent downward momentum.

Dishman Carbogen Amcis Ltd commenced trading on 17 Aug 2026 with a pronounced gap down, reflecting heightened market apprehension. The stock opened 5.02% lower, extending a recent downward trend amid elevated volatility and underperformance relative to its sector and benchmark indices.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 12 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 Feb 2026, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 21 July 2026, providing investors with the latest insights into its performance and prospects.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 Feb 2026, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics presented here are based on the company's current position as of 10 July 2026, providing investors with the latest insights into the stock's performance and outlook.

The Sensex advanced 0.71% on 2 Jul 2026, yet Dishman Carbogen Amcis Ltd outpaced the broader market with a 7.77% gain, reaching an intraday high of Rs 189. This 6.99 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a mere market tailwind.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 04 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 18 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 February 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 February 2026, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 February 2026, reflecting a reassessment of the stock’s outlook. However, the analysis below is based on the company’s current fundamentals, returns, and financial metrics as of 08 June 2026, providing investors with an up-to-date view of the stock’s position.

Dishman Carbogen Amcis Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a recent downgrade to a Strong Sell rating by MarketsMOJO, the stock exhibits a complex interplay of technical indicators that suggest cautious investor sentiment amid mixed signals.

Dishman Carbogen Amcis Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest day gain of 1.18%, the stock’s broader technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, reflecting cautious investor sentiment amid ongoing market volatility.